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CASE REPORT
A 75-year-old South-East Asian man presented with
exertional chest pain. Risk factors for coronary disease
included hypertension, diabetes mellitus, hyperlipi-
daemia, and family history. High sensitivity Troponin
was normal. An electrocardiogram (ECG) showed sinus
rhythm with deep T wave inversion in leads I, aVL, V4–
V6 (Figure 1). Coronary angiography showed diffuse,
non-obstructive disease (Figure 2). Rubidium-82 posi-
tron-emission tomography (PET) imaging demonstrated
increased tracer uptake at rest, suggestive of left
ventricular (LV) hypertrophy. There was adenosine
stress-induced LV cavity dilation with reversible hypop-
erfusion in a left anterior descending artery territory
(Figure 3A). The global myocardial perfusion reserve
(MPR) was reduced at 1.22 ml/g/min (Figure 3B). In
view of the resting ECG abnormality, high tracer uptake
at rest and reduced global in the context of non-
obstructed coronaries, cardiac magnetic resonance
(CMR) imaging (3T Skyra) was performed to exclude
a cardiomyopathy. This demonstrated marked regional
variability in heart muscle thickness with a maximal
wall thickness of 19 mm in the mid inferoseptum
(Figure 4A). Left ventricular ejection fraction was
supranormal (82%) with apical systolic cavity obliter-
ation (see on-line Video A). Although there was only
minimal late gadolinium enhancement seen involving
the superior right ventricular insertion point (image not
shown), native T1 was elevated at 1276 ms consistent
with diffuse fibrosis (mid septum, normal range
1052 ± 23 ms; Figure 4B). Adenosine stress imaging
demonstrated a circumferential epicardial-endocardial
signal intensity gradient, most pronounced in areas of
maximal myocardial thickness (Figure 4C, arrows; on-
line Video B).
DISCUSSION
This case highlights the ability of both PET and
CMR imaging to demonstrate impaired myocardial
blood flow during vasodilator stress with adenosine in
a patient with hypertrophic cardiomyopathy (HCM). In
the absence of a coronary stenosis, these findings are
consistent with microvascular dysfunction. Numerous
pathophysiological factors have been implicated in the
development of small vessel ischemia in HCM including
thickening of intramural coronary arterioles, elevated
regional wall stress associated with increased intra-
cavity pressures resulting from outflow obstruction,
disorganized cellular architecture with increased colla-
gen deposition in the interstitium, and ventricular
hypertrophy associated with a decrease in capillary
density.1 In a study of 34 patients with HCM who
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underwent combined PET and CMR imaging, Sotgia
et al. demonstrated a continuum of coronary microvas-
cular ischemia ranging from those subjects with only
mildly elevated wall thickness in whom hyperemic
myocardial blood flow (MBF) is relatively preserved
and late gadolinium enhancement absent, to those with
greater hypertrophy, where MBF is increasingly
impaired and replacement fibrosis more frequent and
extensive.2 Similarly, pixel-wise quantitative CMR per-
fusion imaging in 35 HCM patients demonstrated an
inverse association between hyperemic MBF and wall
thickness, with a significantly lower probability of
fibrosis in myocardial segments with increasing hyper-
emic MBF.3 These data provide support for the
hypothesis that coronary microvascular dysfunction
contributes to the development of myocardial fibrosis
Figure 1. A 12-lead electrocardiogram showed sinus rhythm with T wave inversion in I, aVL, V4–
V6 and fulfilled voltage criteria for left ventricular hypertrophy.
Figure 2. Angiography of the right (A) and left (B) coronary arteries showing diffuse atheroma
with non-flow limiting disease.
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in HCM. Although in our case there was limited
evidence of replacement fibrosis, T1-mapping was
consistent with diffuse fibrosis, and this was associated
with reduced hyperemic MBF and global MPR. We also
demonstrated transient ischemic dilatation on PET
which has been reported in up to half of HCM patients
without epicardial coronary disease;4 this observation is
also associated with reduced maximal global hyperemic
MBF and MPR, as well as greater maximal wall
thickness on echocardiography.4,5 More recently, PET
imaging of 104 HCM patients demonstrated stress-
induced LV cavity dilatation in 52% and this was
associated with the stress trans-mural perfusion gradient,
reduced global MPR and lower stress LV ejection
fraction.6
The presence of microvascular dysfunction in
patients with HCM has long been recognized as a strong
predictor of clinical deterioration and mortality: in 2003,
Cecchi et al. used PET to identify a stress MBF of
\ 1.10 ml/g/min as the optimal cut-off for predicting
adverse events.7 Further long-term outcome studies are
required to clarify this threshold and to determine
whether this phenomenon provides incremental prog-
nostic utility beyond the factors already entered into the
current HCM risk algorithm.8
Figure 3. Rubidium-82 positron-emission tomography imaging showed increased tracer uptake at
rest, suggestive of left ventricular hypertrophy. Transient ischaemic dilatation was noted with
evidence of reversible hypoperfusion in a left anterior descending artery territory (A). The maximal
global blood flow and the global myocardial perfusion reserve were both reduced (B).
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Figure 4. Steady-state free precession cine imaging (A and see on-line Video A) demonstrated
asymmetric septal hypertrophy with a maximal wall thickness of 19 mm in the mid inferoseptum
(see caliper). Left ventricular ejection fraction was supranormal (82%) with apical systolic cavity
obliteration. Pre-contrast (native) T1 was increased in the mid septum at 1276 ms consistent with
diffuse fibrosis (normal range 1052 ± 23 ms; B). Adenosine stress imaging demonstrated a
circumferential epicardial–endocardial signal intensity gradient, most pronounced in the basal and
mid septal wall—the area of maximal myocardial wall thickness (C).
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